National Bank of Canada’s BioCryst Pharmaceuticals BCRX Stock Holding History

National Bank of Canada’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$54.3K	Buy	5,700 +5,200	+1,040%	+$40.4K	﹤0.01%	1958
2025 Q4	$3.9K	Buy	+500	New	+$3.62K	﹤0.01%	2479
2024 Q3	–	Sell	-500	Closed	-$3.32K	–	2771
2024 Q2	$3.32K	Hold	500	–	–	﹤0.01%	2350
2024 Q1	$2.66K	Hold	500	–	–	﹤0.01%	2412
2023 Q4	$3.03K	Sell	500 -214	-30%	-$1.24K	﹤0.01%	2405
2023 Q3	$4.79K	Buy	714 +214	+43%	+$1.54K	﹤0.01%	2358
2023 Q2	$3.51K	Hold	500	–	–	﹤0.01%	2408
2023 Q1	$4.17K	Hold	500	–	–	﹤0.01%	2331
2022 Q4	$5.73K	Hold	500	–	–	﹤0.01%	2299
2022 Q3	$6K	Hold	500	–	–	﹤0.01%	2298
2022 Q2	$5K	Hold	500	–	–	﹤0.01%	2413
2022 Q1	$8K	Hold	500	–	–	﹤0.01%	2437
2021 Q4	$7K	Buy	+500	New	+$6.62K	﹤0.01%	2451

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

National Bank of Canada's BCRX Position: Q1 2026 in Review

National Bank of Canada increased its BioCryst Pharmaceuticals (BCRX) stake by 1,040% in Q1 2026, buying an estimated $40.4K and bringing the position to 5,700 shares worth $54.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

National Bank of Canada first reported a position in BCRX in Q4 2021 and has held it in 13 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

National Bank of Canada held 5,700 shares of BioCryst Pharmaceuticals worth $54.3K as of Q1 2026.
National Bank of Canada bought 5,200 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $40.4K.
BioCryst Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #1958 holding.
National Bank of Canada first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.